Stereotactic Body Radiation Therapy for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how stereotactic body radiation therapy affects the immune system's CD8+ T cells. These cells play a crucial role in infiltrating and killing tumor cells, potentially aiding in cancer control. The trial includes patients with lymphoma and those with metastatic solid tumors to determine if radiation can effectively recruit these cells to combat cancer. Candidates should have a solid tumor treatable with this radiation type and should not have changed their treatment plan in the last two months. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does require no change in your systemic treatment regimen for 2 months before starting the radiation therapy. It's best to discuss your specific medications with the trial team.
What prior data suggests that this radiation therapy is safe?
Research has shown that Stereotactic Body Radiation Therapy (SBRT) is generally safe and well-tolerated. Studies have found positive results, particularly for patients with certain types of cancer. For instance, patients with oligometastatic cancer—a condition where cancer has spread but remains limited in number and location—have found SBRT both safe and manageable.
Intensity Modulated Radiation Therapy (IMRT) is also considered safe. One study found that IMRT reduced long-lasting side effects compared to traditional radiation methods, meaning patients may experience fewer side effects over time.
Both SBRT and IMRT have demonstrated promising safety in previous research. These therapies target tumors more precisely, helping to limit damage to healthy tissues. This precision reduces the chance of harmful side effects. While side effects can occur, evidence suggests these treatments are generally well-tolerated by patients.12345Why are researchers excited about this trial?
Researchers are excited about this approach because Stereotactic Body Radiation Therapy (SBRT) offers precise targeting of tumors, which could reduce damage to surrounding healthy tissue compared to traditional radiation therapy options like External Beam Radiation Therapy (EBRT). SBRT allows for higher doses of radiation to be delivered in fewer sessions, potentially improving treatment outcomes and convenience for patients. Additionally, the use of zirconium Zr 89-Df-crefmirlimab in combination with PET imaging could enhance the accuracy of tumor targeting, further boosting the efficacy and safety of the treatment.
What evidence suggests that Stereotactic Body Radiation Therapy could be effective for cancer?
Research has shown that Stereotactic Body Radiation Therapy (SBRT), one of the treatments in this trial, effectively controls tumors. One study found that 89.1% of tumors did not grow for two years after treatment. Another study showed that 88% of tumors either completely or partially shrank.
For Intensity Modulated Radiation Therapy (IMRT), which may be used for lymphoma patients in this trial, research indicates it effectively treats lymphoma. One study reported that 68% of patients were still alive five years after treatment, suggesting a good long-term survival rate. Another study found that patients treated with IMRT had better overall outcomes compared to another method.678910Who Is on the Research Team?
Savita Dandapani, MD
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
Adults (18+) with lymphoma or solid tumor malignancies suitable for radiation therapy, able to follow the trial's procedures. They must have stable treatment for 2 months prior and be willing to undergo daily PET scans post-radiation. Women of childbearing age need a negative pregnancy test and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive zirconium Zr 89-Df-crefmirlimab IV and undergo PET imaging before and after SBRT. SBRT is administered every 2-5 days for a total of 5 fractions.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with follow-up visits at 4-6 weeks, 3 months, 1 year, and periodically for 2 years.
What Are the Treatments Tested in This Trial?
Interventions
- Intensity Modulated Radiation Therapy
- Positron Emission Tomography
- Stereotactic Body Radiation Therapy
Intensity Modulated Radiation Therapy is already approved in United States, European Union, Canada, Japan, China for the following indications:
- Various types of cancer, including but not limited to prostate cancer, head and neck cancer, lung cancer, breast cancer, brain tumors, and spinal tumors
- Various types of cancer, including but not limited to prostate cancer, head and neck cancer, lung cancer, breast cancer, brain tumors, and spinal tumors
- Various types of cancer, including but not limited to prostate cancer, head and neck cancer, lung cancer, breast cancer, brain tumors, and spinal tumors
- Various types of cancer, including but not limited to prostate cancer, head and neck cancer, lung cancer, breast cancer, brain tumors, and spinal tumors
- Various types of cancer, including but not limited to prostate cancer, head and neck cancer, lung cancer, breast cancer, brain tumors, and spinal tumors
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator